Humble, Management have executed on time and within budget since...

Humble, Management have executed on time and within budget since starting with ACW. They have completed a Phase 1 study successfully and have begun a fully funded Phase 2 study with likely IDE announcements imminent and First patient recruitment in June. This is a Blinded trial in 3 countries, being Australia, United States and England with approx 200 participants. The compound has had human trials previously for diabetes that were statistically significant and as an aside indicators were picked up for improved memory amongst the participants. The compound though was found to have unacceptable levels of toxicity and has been modulated and subsequently has been cleared Phase 1 safety. The MD is Dr Bill Ketelby ex Pfizer who specialised in Alzheimer drugs.
I think Baker stock broking has a research report which would be on ACW website.
After hearing nothing from the company for 12 months as they put everything together it is about to begin. Google Phase 2 Alzheimer companies and do the comparison for ACW and in my opinion make this company pretty attractive.